ReviewOrphanet journal of rare diseases2025
Thalassemia in Bangladesh: progress, challenges, and a strategic blueprint for prevention.
Review in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Pancreatic Iron Overload Is Associated With Early QTc Prolongation Before Myocardial Iron Deposition in Transfusion-Dependent Thalassemia.European journal of haematology · 2026Article
- Thalassemia in Iraq: Time to Reform Policy.Rwanda journal of medicine and health sciences · 2026Article
- Diagnostic performance of discriminant formulas and machine learning models for detecting β-thalassemia trait in Bangladesh.PloS one · 2026Article
- Clinical, Hematological, and Nutritional Profiling of Thalassemia Patients: Insights From a Cross-Sectional Study.Anemia · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thalassemia, a preventable hereditary disorder causing defective hemoglobin production, presents a growing public health concern in Bangladesh, a country situated within the Global Thalassemia Belt. This review systematically synthesizes all available data on the prevalence, clinical characteristics, management challenges, and socio-economic implications of thalassemia in Bangladesh, offering a blueprint for a prevention strategy tailored to its unique socio-economic and cultural context. The review highlights a high carrier prevalence of 10.9-13.3%, translating to approximately 17-22 million carriers, with significant regional and ethnic variations, including a disproportionately high E-trait prevalence. Most transfusion-dependent thalassemia cases in Bangladesh are Hb E-Beta Thalassemia. With proper care, many patients can avoid regular transfusions. However, clinical management remains inadequate due to insufficient healthcare infrastructure, poor access to safe blood transfusions, limited iron chelation therapy, and a lack of multidisciplinary care. These gaps are compounded by socio-economic barriers, with most patients bearing 74% of treatment costs out-of-pocket, leaving many deprived of adequate care. Building on successful international prevention models from countries such as Cyprus, Iran, and Italy, the paper proposes a high school-centric intervention strategy for Bangladesh. This includes awareness campaigns, carrier screening, and genetic counseling targeted at adolescents, coupled with the integration of thalassemia education into school curricula. Additionally, it calls for the establishment of district-level treatment centers, a national patient registry, and policies to subsidize treatment costs. Despite the cultural and logistical challenges, the review underscores the urgent need to prioritize awareness, early diagnosis, and prevention over treatment. It emphasizes that thalassemia is theoretically 100% preventable through premarital screening and prenatal diagnosis if implemented with religious and cultural sensitivity. By providing a roadmap for a comprehensive thalassemia prevention and management strategy, this review aims to guide policymakers and stakeholders while improving the quality of life for existing patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.